Psychiatric DisorderPSYCHEQUALINCT06014164
Qualitative Study About Psychedelics Using in Psychiatric Disorders
An observational study of Psychiatric Disorder, run by University Hospital, Toulouse at 1 site in France.
Trial summary
This study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Psychiatric Disorder
- What is being tested?
- Interview
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- 30 Nov 2023to 15 Nov 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults patients self-administering psychodelic substances for therapeutic purposes
Who may be able to join
- Patients diagnosed with a psychiatric disorder by a psychiatrist or general practitioner
- Patients used psychedelic or related substances in order to treat psychiatric symptoms
- Patients have given their oral non-opposition
- Patients affiliated to a social security scheme
Who cannot join
- Patients who don't speak or understand French
- Patients under protection, guardianship or curators
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Qualitative Study of the Self-administered Therapeutic Use of Psychedelics in People With Psychiatric Disorders
This study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. The data are collected during a semi-structured interview and then studied in a thematic analysis.
- Conditions
- Psychiatric Disorder
- Being tested
- Interview
- Keywords
- Psychiatric disorder, Psychedelics
- Medical subject headings
- Mental Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewDiagnostic test
An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes
| Study group | Role | What they receive |
|---|---|---|
| Patients using psychedelic substances | Adult patients self-administering psychedelic substances in psychiatric disorders Receives: Diagnostic Test: Interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
Experiences of people using psychedelic substances
Experiences description of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview
Measured: Baseline
Secondary outcomes (1)
Profile of people using psychedelic substances
The profile of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2023
- Study start30 Nov 2023
- Primary completion15 Nov 2024
- Study completion15 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psychiatric DisorderStudies of the same condition, open and under way.
- More trials run by University Hospital, ToulouseThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Toulouse
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Antoine YRONDI, MD, Principal investigator, University Hospital, Toulouse
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06014164
- Sponsor's protocol ID
- RC31/23/0396
- Other IDs
- 2023-A01575-40
- Acronym
- PSYCHEQUALI
- Status last verified
- Jul 2026
- First submitted
- 22 Aug 2023
- Last updated
- 23 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Qualitative Study of the Self-administered Therapeutic Use of Psychedelics in People With Psychiatric Disorders
- ClinicalTrials.gov ID
- NCT06014164
- Acronym / sponsor ID
- PSYCHEQUALI / RC31/23/0396
- Conditions
- Psychiatric Disorder
- Keywords
- Psychiatric disorder, Psychedelics
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University Hospital, ToulouseUniversity, hospital or other
- Study start
- 30 Nov 2023 (actual)
- Primary completion
- 15 Nov 2024 (actual)
- Study completion
- 15 Nov 2024 (actual)
- First posted
- 28 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. The data are collected during a semi-structured interview and then studied in a thematic analysis.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients using psychedelic substances | – | Diagnostic Test: InterviewAdult patients self-administering psychedelic substances in psychiatric disorders |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults patients self-administering psychodelic substances for therapeutic purposes
Key inclusion criteria (4 listed)
- Patients diagnosed with a psychiatric disorder by a psychiatrist or general practitioner
- Patients used psychedelic or related substances in order to treat psychiatric symptoms
- Patients have given their oral non-opposition
- Patients affiliated to a social security scheme
Key exclusion criteria (2 listed)
- Patients who don't speak or understand French
- Patients under protection, guardianship or curators
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterviewAn interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes | Diagnostic test | Patients using psychedelic substances |
Primary outcome
Experiences of people using psychedelic substances
Time frame: Baseline
Experiences description of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview
1 secondary outcome
Profile of people using psychedelic substances
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
Related trials for Psychiatric Disorder
RecruitingObservational study
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Alcoholism, Substance-Related Disorders
Recruiting
Inspiratory Muscle Training and Diaphragmatic Breathing in GAD
Generalized Anxiety Disorder (GAD)
RecruitingObservational study
Rigid Hymenal Ring as a Cause for Insertional Dyspareunia
Dyspareunia (Female)
Active, not recruitingObservational study
The Effect of Single Lung Ventilation Duration and Intraoperative Brain Oxygenation on Cognitive Function and Postoperative Pain in Geriatric Patients
Thoracic Anesthesia, Geriatric Anesthesia
Enrolling by invitationObservational study
Trajectory Study: Predicting Cardiometabolic Health in Adolescents and Young Adults Based on Childhood Fitness, Sleep, and Diet
Cardiometabolic Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Antoine YRONDI, MD principal investigator
University Hospital, Toulouse
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psychiatric Disorder, run by University Hospital, Toulouse at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Experiences of people using psychedelic substances (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.